Discover and read the best of Twitter Threads about #AlembicPharma
Most recents (3)
#AlembicPharma Q3 FY22 concall highlights
Like & Retweet for better reach !
1. Revenues for the quarter stood at ₹1272 Cr (3% decline YoY).
2. EBITDA for the quarter was ₹269 Cr (33% decline YoY). EBITDA margin was at 21% for the quarter.
Like & Retweet for better reach !
1. Revenues for the quarter stood at ₹1272 Cr (3% decline YoY).
2. EBITDA for the quarter was ₹269 Cr (33% decline YoY). EBITDA margin was at 21% for the quarter.
3. PAT stood at 176 Cr (40% decline YoY).
4. They believe the price erosion in the US business has normalized and they can grow with new launches from here on.
4. They believe the price erosion in the US business has normalized and they can grow with new launches from here on.
5. They have a couple of first-to-file launches coming up in FY23.
6. R&D expenditure for the quarter was at ₹154 Cr which is about 12% of sales. They have filed 6 ANDAs during the quarter.
6. R&D expenditure for the quarter was at ₹154 Cr which is about 12% of sales. They have filed 6 ANDAs during the quarter.
1 new chart everyday, it could be from any space ~ equities / commodities / crypto / forex / bonds , etc
Will try to do it daily 🙏💪
Here's the first one 👇
SBI vs BankNifty
Ratio chart has given monthly breakout implying SBI could outperform BN in coming months.
#PB365
Will try to do it daily 🙏💪
Here's the first one 👇
SBI vs BankNifty
Ratio chart has given monthly breakout implying SBI could outperform BN in coming months.
#PB365
#AlembicPharma Good potential. 2500 Cr Capex till 2021 ongoing. Entered in high margin injectable business. Capex on Oncology injectable facility ongoing. Injectables have more stringent FDA requirements than oral dosages. Hence less competitive.
RnD expenditure is an important parameter for identifying the future potential for a pharma company. 650 Cr spent in 2020. This should reflect in earnings in the coming years. The stock price might discount this before 2021.
New Drug Discovery unit:
